Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Adv Sci (Weinh). 2024:e2303752.

Li J, Chin CR, Ying H-, Meydan C, Teater MR, Xia M, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024;15(1):2879.

Javdan B, Marwaha S, Magro C, Wassef C. Pink Papules on the Cheek. Cutis. 2024;113(1):10-17.

Cavallaro J, Singha S, Chakrabarti B, Gopalakrishnan E, Harshan M, Pramanik BK, et al. Symptomatic infratentorial ependymal cyst arising from the medulla: a case report with review of literature. Neurochirurgie. 2024;70(4):101553.

Smithgall MC, Yemelyanova A, Mathew S, Gogineni S, He B, Zhang T, et al. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors. Int J Gynecol Pathol. 2024;43(2):134-139.

Chan AT, Maya TR, Park C, Tak K, Liberman N, Jain RH, et al. Incremental Utility of First-Pass Perfusion CMR for Prognostic Risk Stratification of Cancer-Associated Cardiac Masses. JACC Cardiovasc Imaging. 2024;17(2):128-145.

Kim D, Thrall MJ, Michelow P, Schmitt FC, Vielh PR, Siddiqui MT, et al. The current state of digital cytology and artificial intelligence (AI): global survey results from the American Society of Cytopathology Digital Cytology Task Force. J Am Soc Cytopathol. 2024;13(5):319-328.

Kudman S, Semaan A, Assaad MA, Gogineni S, M Martin L, Mathew S, et al. Optimization of Fluorescence In Situ Hybridization Protocols in the Era of Precision Medicine. Curr Protoc. 2024;4(6):e1093.

Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.

Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Res Sq. 2024.